Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

2015 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
12/18/15Portola Pharmaceuticals Completes BLA Submission to U.S. Food and Drug Administration for Andexanet Alfa
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today completion of the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its investigational agent andexanet alfa, an FDA-designated breakthrough therapy specifically designed to reverse the anticoagulant activity of both direct and indirect Factor Xa inhibitors. Portola is developing andexanet alfa as a universal reversal ag... 
Printer Friendly Version
12/05/15Portola Pharmaceuticals Announces Andexanet Alfa and Cerdulatinib Data Presentations at the 2015 American Society of Hematology Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced the presentation of new results from clinical and non-clinical studies of two of its investigational pipeline products – the Factor Xa inhibitor reversal agent andexanet alfa and the oral, dual Syk/JAK kinase inhibitor cerdulatinib – at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. Andexanet alfa, a U.S. Food and Drug Administrat... 
Printer Friendly Version
12/04/15Portola Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today the pricing of its underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $48.00 per share.  In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 468,750 shares from Portola at the public offering price. The offering is expected to close on December 9, 2015, subject to cust... 
Printer Friendly Version
12/03/15Portola Pharmaceuticals Announces Proposed Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced plans to offer, subject to market and other conditions, 2,600,000 shares of its common stock in an underwritten public offering.  The company expects to grant the underwriters a 30-day option to purchase up to an additional 390,000 shares of common stock in connection with the offering.  All of the shares of common stock in the offering will be sold by Portola Pharmaceutic... 
Printer Friendly Version
11/12/15Portola Pharmaceuticals to Host Analyst and Investor Day on November 19
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today that it will host an Analyst and Investor Day on Thursday, November 19. The event is scheduled to take place from 8-11:30 a.m. Eastern Time in New York and will be simultaneously webcast.   Members of Portola’s senior management team will provide an update on recent advances with the Company’s thrombosis and hematologic cancer product pipeline. In addition, the followin... 
Printer Friendly Version
11/11/15The New England Journal of Medicine Publishes Results of Portola Pharmaceuticals’ Phase 3 ANNEXA Studies of Andexanet Alfa
Full Data Set From ANNEXA-R Also Presented Today in Late-Breaking Clinical Trial Session at AHA Scientific Sessions 2015 SOUTH SAN FRANCISCO, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) announced that the results of its  Phase 3 ANNEXA™ (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors) studies were published online today by The New England Journal of Medicine. ANNEXA-R and ANNEXA-A evaluated the safety and efficacy ... 
Printer Friendly Version
11/09/15Portola Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update
Initiated Rolling BLA submission to FDA for Andexanet alfa --Conference Call Today at 4:30 p.m. ET-- SOUTH SAN FRANCISCO, Calif., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today provided a corporate update and reported its financial results for the third quarter ended September 30, 2015.  “We achieved a number of significant clinical, regulatory and manufacturing milestones over the past quarter,” said William Lis, chief executive officer of Portola. “We comp... 
Printer Friendly Version
11/06/15Portola Pharmaceuticals Announces Phase 3 ANNEXA™-R Part 2 Study Results to be Presented at American Heart Association Scientific Sessions 2015
Full Results of Andexanet Alfa and Rivaroxaban Part 2 Study to be Featured in Late-Breaking Clinical Trial Oral Session on November 11th South San Francisco, Calif., Nov. 06, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that full data from the second part of its Phase 3 ANNEXA™-R (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Rivaroxaban) study of the investigational agent andexanet alfa will be presented during a Late-Break... 
Printer Friendly Version
11/04/15Portola Pharmaceuticals to Present at Credit Suisse 24th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Credit Suisse 24th Annual Healthcare Conference on Wednesday, November 11, at 9:30 a.m. Mountain Standard Time at The Phoenician in Scottsdale, Ariz. The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section. About Portola Pharmaceu... 
Printer Friendly Version
11/02/15Portola Pharmaceuticals to Announce Third Quarter 2015 Financial Results and Host Conference Call on Monday, November 9
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended September 30, 2015, and provide a general business overview on Monday, November 9, 2015 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Conference Call Details To access the live conference call, please dial (844) 452-6828 from the U.S. and Canada or +1(765) 507... 
Printer Friendly Version
10/30/15Portola Pharmaceuticals Completes Enrollment in Pivotal Phase 3 APEX Study of Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients
--Company Expects to Report Top-Line Results at End of First Quarter 2016-- --Betrixaban Has Potential to Become First Oral Factor Xa Inhibitor Anticoagulant Approved for Prevention of VTE in Acute Medically Ill-- SOUTH SAN FRANCISCO, Calif., Oct. 30, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced it has completed patient enrollment in the pivotal Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study. The 7,500-patient s... 
Printer Friendly Version
10/13/15Portola Pharmaceuticals Announces FDA Grants Fast Track Designation to Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients
Betrixaban Has Potential to Become First Oral Factor Xa Inhibitor Anticoagulant Approved for Hospital-to-Home Prevention of Venous Thromboembolism in Acute Medically Ill Patients SOUTH SAN FRANCISCO, Calif., Oct. 13, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to betrixaban for extended-duration prevention of venous thromboembolism (VTE), or blood clots, in acute medically il... 
Printer Friendly Version
09/24/15Portola Pharmaceuticals Appoints Dr. David C. Stump to Board of Directors
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced the appointment of David C. Stump, M.D., to its board of directors. Dr. Stump most recently served as executive vice president, research and development, at Human Genome Sciences, Inc. "Dr. Stump has over 25 years of experience, most notably at Genentech and Human Genome Sciences, bringing some of the most successful drugs for heart disease, stroke, B-cell lymphoma and other ... 
Printer Friendly Version
09/15/15Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints
New Topline Data From Pivotal Study Demonstrate Sustained Reversal of Anticoagulant Effect of Factor Xa Inhibitor Rivaroxaban Following Administration of Portola's FDA-Designated Breakthrough Therapy SOUTH SAN FRANCISCO, Calif., Sept. 15, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that the second part of its Phase 3 ANNEXA™-R (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Rivaroxaban) study achieved all primary and secondary... 
Printer Friendly Version
09/10/15Portola Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Morgan Stanley Global Healthcare Conference on Thursday, September 17, at 11:10 a.m. Eastern Time at the Grand Hyatt New York. The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section. About Portola Pharmaceuticals, Inc. Por... 
Printer Friendly Version
08/27/15Portola Pharmaceuticals to Present Preclinical Data with Andexanet Alfa and Factor Xa Inhibitor Edoxaban at European Society of Cardiology Congress 2015
SOUTH SAN FRANCISCO, Aug. 27, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq: PTLA) today announced that results of a preclinical study of andexanet alfa will be presented in a moderated poster session at the European Society of Cardiology (ESC) 2015 Congress in London, U.K. The study assessed the activity of andexanet alfa in reversing anticoagulation and reducing bleeding in a validated animal model using Daiichi Sankyo's oral, once-daily, direct Factor Xa inhibitor edoxaban as the a... 
Printer Friendly Version
08/04/15Portola Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update
Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today provided a corporate update and reported its financial results for the second quarter ended June 30, 2015. "We continue to make solid progress toward near-term significant milestones that will allow us to launch two of our late-stage thrombosis products that target multi-billion dollar hospital-based markets – andexanet alfa in 2016 and betrixaban i... 
Printer Friendly Version
07/28/15Portola Pharmaceuticals to Announce Second Quarter 2015 Financial Results and Host Conference Call on Tuesday, August 4
SOUTH SAN FRANCISCO, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended June 30, 2015, and provide a general business overview on Tuesday, August 4, 2015, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Conference Call Details To access the live conference call, please dial (844) 452-6828 from the U.S. and Canada or +1 (765) 507... 
Printer Friendly Version
06/24/15Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin Complex Concentrate Did Not
Data Presented at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress SOUTH SAN FRANCISCO, Calif., June 24, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced results of a study demonstrating that andexanet alfa significantly reduced bleeding in a validated animal model of bleeding using the Factor Xa inhibitor rivaroxaban as the anticoagulant. The reduction in blood loss correlated with reversal of the anticoagulant effects of rivaroxaban as mea... 
Printer Friendly Version
06/22/15Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3 ANNEXA-A(TM) Study Demonstrating That Investigational Andexanet Alfa Sustained Reversal of Anticoagulant Effect of Factor Xa Inhibitor Eliquis (apixaban)
Data Presented Today in Late-Breaking Clinical Trial Oral Session at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress SOUTH SAN FRANCISCO, Calif., PRINCETON, N.J. and NEW YORK, June 22, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA), Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced full results from the second part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – A... 
Printer Friendly Version
06/15/15Portola Pharmaceuticals Appoints Industry Leader Tao Fu as Executive Vice President, Chief Commercial and Business Officer
Addition Strengthens Leadership Team as Company Advances Three Potentially Groundbreaking Products in Thrombosis and Hematologic Cancer SOUTH SAN FRANCISCO, Calif., June 15, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced the appointment of Tao Fu as executive vice president, chief commercial and business officer, effective immediately. Mr. Fu joins Portola from Bristol-Myers Squibb (BMS), where he was vice president and head of mergers and acquisitions and allian... 
Printer Friendly Version
06/09/15Portola Pharmaceuticals Announces Upcoming Data Presentations on Andexanet Alfa at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress
--Full Results of Second Part of ANNEXA™-Apixaban Study and Results of Andexanet Alfa Vs. Four-Factor Prothrombin Complex Concentrate Study to be Featured in Oral Sessions-- South San Francisco, Calif. (June 9, 2015) – Portola Pharmaceuticals (Nasdaq: PTLA) today announced that data from its clinical development program for the investigational agent andexanet alfa will be highlighted in oral sessions at the upcoming International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress... 
Printer Friendly Version
06/03/15Portola Pharmaceuticals to Present at Goldman Sachs 36th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 3, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Goldman Sachs 36th Annual Global Healthcare Conference on Wednesday, June 10, at 8:00 a.m. Pacific Time in Rancho Palos Verdes, Calif. The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section. About Portola Pharmaceuticals, Inc. ... 
Printer Friendly Version
05/29/15Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib
--Oral, Dual Syk-JAK Kinase Inhibitor Continues to Demonstrate Clinical Proof of Concept in Hematologic Cancer Patients Who Have Failed Prior Therapies-- SOUTH SAN FRANCISCO, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced updated positive safety and efficacy data from the Phase 1 part of its ongoing Phase 1/2a proof-of-concept study of cerdulatinib in patients with hematologic cancers who have failed multiple therapies. Cerdulatinib is an oral, du... 
Printer Friendly Version
05/18/15Portola Pharmaceuticals Announces Upcoming Data Presentation on Dual Kinase Inhibitor Cerdulatinib at American Society of Clinical Oncology (ASCO) Annual Meeting
--Updated Safety and Efficacy Data From Phase 1 Part of Ongoing Phase 1/2a Study to be Presented-- --Company Opens Enrollment in Expansion Cohorts in Phase 2a Part of Study-- SOUTH SAN FRANCISCO, Calif., May 18, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it will present updated safety and efficacy data from the Phase 1 part of its ongoing Phase 1/2a proof-of-concept study of cerdulatinib in patients with hematologic cancers who have failed multipl... 
Printer Friendly Version
05/06/15Portola Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update
Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 6, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today provided a corporate update and reported its financial results for the first quarter ended March 31, 2015. "This is a monumental year for the company," said William Lis, chief executive officer of Portola. "We are now approximately one year from the potential launch of our first commercial product, andexanet alfa, in 2016 followed by a second product... 
Printer Friendly Version
05/05/15Portola Pharmaceuticals Announces Collaboration With Ora, Inc. for Syk-selective Inhibitor (PRT2761) in Ophthalmic Diseases
Collaboration Allows Portola to Advance Product Candidates Outside of Core Focus While Retaining Economics and Flexibility for Future Development SOUTH SAN FRANCISCO, Calif., May 5, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced a collaboration with Ora, Inc. for the development of Portola's highly selective Syk inhibitor, PRT2761, in ophthalmic diseases. The inhibition of Syk may more completely prevent activation of mast cells in ocular allergy and, therefore, ... 
Printer Friendly Version
05/05/15Portola Pharmaceuticals to Present at Bank of America Merrill Lynch 2015 Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 5, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, at 10:00 a.m. Pacific Time in Las Vegas. The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section. About Portola Pharmaceuticals, Inc. Portola Pharma... 
Printer Friendly Version
04/29/15Portola Pharmaceuticals to Announce First Quarter 2015 Financial Results and Host Conference Call on Wednesday, May 6
SOUTH SAN FRANCISCO, Calif., April 29, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended March 31, 2015, and provide a general business overview on Wednesday, May 6, 2015, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Conference Call Details To access the live conference call, please dial (877) 415-3182 from the U.S. and Canada or +1(857) 244... 
Printer Friendly Version
04/08/15Portola Pharmaceuticals Announces New Topline Data From Phase 3 ANNEXA-A(TM) Trial Part 2: Breakthrough Designated Andexanet Alfa Successfully Meets Primary Endpoint for Prolonged Reversal of Factor Xa Inhibitor Eliquis (apixaban)
Data Support Potential Registration of Andexanet Alfa Bolus-Only and Bolus-Plus-Continuous-Infusion Dosing Regimens to Reverse Anticoagulant Effect of Factor Xa Inhibitors SOUTH SAN FRANCISCO, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced positive topline results from the second part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Apixaban) study, which evaluated the safety and effi... 
Printer Friendly Version
03/10/15Portola Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., March 10, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today the pricing of its underwritten public offering of 2,495,652 shares of its common stock at a price to the public of $40.00 per share. In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 374,348 shares from Portola at the public offering price. The offering is expected to close on March 13, 2015, subject to customar... 
Printer Friendly Version
03/09/15Portola Pharmaceuticals Announces Proposed Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., March 9, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that it has commenced an underwritten public offering of shares of its common stock and expects to raise gross proceeds of approximately $100,000,000. All of the shares of common stock in the offering will be sold by Portola Pharmaceuticals. Subject to market and other conditions, the offering is expected to price before 9:30 a.m., EDT, on March 10, 2015. Morgan Stanley ... 
Printer Friendly Version
03/02/15Portola Announces Full Results From Positive Phase 3 ANNEXA(TM)-R Study Demonstrating That Andexanet Alfa Rapidly and Significantly Reversed Anticoagulant Effect of Factor Xa Inhibitor XARELTO(R)
Presentation in Oral Session at American College of Cardiology's (ACC) 64th Annual Scientific Session on Monday, March 16 SOUTH SAN FRANCISCO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced full results from the first part of the Phase 3 ANNEXA™-R (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXa Inhibitors – Rivaroxaban) study, which is evaluating the safety and efficacy of andexanet alfa with the Factor Xa inhibitor XARELTO® ... 
Printer Friendly Version
03/02/15Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2014 Financial Results and Provides Corporate Update
Conference Call Today at 8:30 a.m. ET SOUTH SAN FRANCISCO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today provided a corporate update and reported its financial results for the fourth quarter and year ended December 31, 2014. "We are off to a terrific start in 2015 as we build on the momentum we established in 2014. We achieved several important clinical, regulatory and manufacturing milestones that put us on track to achieve our goal of launching thre... 
Printer Friendly Version
02/26/15Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Andexanet Alfa, Its Breakthrough-Designated Factor Xa Inhibitor Antidote
-- Annually, Over 100,000 U.S. Patients Currently Impacted; Projected to Grow Up to 200,000 U.S. Patients by 2020 -- SOUTH SAN FRANCISCO, Calif., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, has been granted orphan drug designation by the FDA's Office of Orphan Products Development for reversing the anticoagulant effect of direct or indirect Factor Xa inhibi... 
Printer Friendly Version
02/25/15Portola Pharmaceuticals to Present at the Cowen and Company 35th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3, 2015 at 8:40 a.m. Eastern Time in Boston. The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section. About Portola Pharmaceuticals, Inc. Portola P... 
Printer Friendly Version
02/24/15Portola Pharmaceuticals to Announce Fourth Quarter and Year End 2014 Financial Results and Host Conference Call on Monday, March 2
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter and year ended December 31, 2014, and provide a general business overview on Monday, March 2, 2015, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). Conference Call Details To access the live conference call, please dial (877) 280-4958 from the U.S. and Canada or +... 
Printer Friendly Version
02/09/15Portola Pharmaceuticals Appoints Two Biotechnology Industry Veterans, Laura Brege and Dr. Dennis Fenton, to Board of Directors
SOUTH SAN FRANCISCO, Calif., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced the appointment of Laura Brege and Dennis Fenton, Ph.D., to its board of directors. Ms. Brege serves as president and chief executive officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Dr. Fenton is the owner and chief executive officer of Fenton and Associates, a biotechnology consulting firm. "Laura and Dennis have directly relevan... 
Printer Friendly Version
02/05/15Portola's Factor Xa Inhibitor Betrixaban Successfully Passes Futility Analysis in Phase 3 APEX Study; Trial Continues as Planned and Remains on Track for Enrollment Completion by Year-End
Betrixaban Has the Potential to be the First Approved Therapy for Hospital-to-Home Prevention of Fatal Blood Clots for the Over 20 Million High-Risk Acute Medically Ill Patients SOUTH SAN FRANCISCO, Calif., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that the Independent Data Monitoring Committee (IDMC) recommended that the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study of betrixaban continue as planned withou... 
Printer Friendly Version
01/26/15Portola Pharmaceuticals Announces Dr. Robert Califf Retires From the Board of Directors to Accept Position as Deputy Commissioner for Medical Products and Tobacco at the Food and Drug Administration (FDA)
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) announced that Robert Califf, M.D., has retired from Portola's Board of Directors. Dr. Califf has accepted a position as the Deputy Commissioner for Medical Products and Tobacco at the FDA, as announced today in a press release issued by the agency. Dr. Califf was first elected to Portola's Board of Directors in 2012. "On behalf of the Company, I want to thank Rob for his invaluable contribut... 
Printer Friendly Version
01/12/15Portola Pharmaceuticals Initiates Phase 4 Study to Support Accelerated Approval of Andexanet Alfa -- Its Breakthrough-Designated Factor Xa Inhibitor Antidote
Company Plans to Submit Biologics License Application by End of Year SOUTH SAN FRANCISCO, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced the initiation of a single-arm Phase 4 study to support the approval of andexanet alfa by the U.S. Food and Drug Administration (FDA) under an Accelerated Approval pathway. Portola is developing this FDA-designated breakthrough therapy as a universal antidote for patients receiving a Factor Xa inhibitor anticoag... 
Printer Friendly Version
01/09/15Portola Announces Phase 3 ANNEXA-R Study of Andexanet Alfa and Factor Xa Inhibitor XARELTO(R) (rivaroxaban) Met Primary Endpoint With High Statistical Significance
Andexanet Alfa is the Only Universal Factor Xa Inhibitor Antidote Shown to Directly Reverse the Anticoagulant Activity of These Agents in Clinical Studies SOUTH SAN FRANCISCO, Calif., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced topline results from the first part of the Phase 3 ANNEXA™-R (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Rivaroxaban) study, which is evaluating the safety and efficacy of andexanet alfa wit... 
Printer Friendly Version
01/06/15Portola Pharmaceuticals Announces Webcast of Corporate Presentation on January 12, 2015
SOUTH SAN FRANCISCO, Calif., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it will host an investor webcast on Monday, January 12, at 12:00 p.m. Pacific Time (3:00 p.m. Eastern Time), which will coincide with the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco. During the event, Portola's senior management team will provide an update on the Company's recent business progress. To access the live and subsequently archived webcast, go... 
Printer Friendly Version